FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

BIOHARVEST SCIENCES INC.

Suite 1140 – 625 Howe Street Vancouver, BC, V6C 2T6

Item 2. Date of Material Change

September 1, 2020

Item 3. News Release

The news release was issued on September 9, 2020 and was disseminated by Stockwatch.

Item 4. Summary of Material Change

BioHarvest Sciences Inc. ("BioHarvest" or the "Company") announced that it has entered into an Investor Relations Agreement with Justin Meiklem (the "Consultant") to provide investor relations services to the Company. The agreement with the Consultant is effective September 1, 2020.

Item 5. Full Description of Material Change

BioHarvest Sciences Inc. ("BioHarvest") (CSE: BHSC)

BioHarvest is pleased to announce that it has entered into an Investor Relations Agreement with Justin Meiklem (the "Consultant") to provide investor relations services to the Company. The agreement with the Consultant is effective September 1, 2020.

In consideration for the services, the Company will pay the Consultant \$10,000 on a monthly basis. The agreement may be terminated by the Company on 30 days notice. The Company has, subject to regulatory approval, issued the Consultant warrants entitling the Consultant to purchase 300,000 common shares of the Company at a price of \$0.14 per share for a term of 18 months.

Item 6. Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

None.

Item 8. Executive Officer

Zaki Rakib President 604-622-1186

Item 9. Date of Report

September 9, 2020



NR: 1-090920

CSE: BHSC

BIOHARVEST SCIENCES INC. ANNOUNCES INVESTOR CONSULTANT

Vancouver, BC / September 9th, 2020 / BioHarvest Sciences Inc. (the "Company", "BioHarvest") (CSE: BHSC) is pleased to announce that it has entered into an Investor Relations Agreement with Justin Meikelm (the "Consultant") to provide investor relations services to the Company. The agreement with the Consultant is effective September 1, 2020.

In consideration for the services, the Company will pay the Consultant \$10,000 on a monthly basis. The agreement may be terminated by the Company on 30 days-notice. The Company has, subject to regulatory approval, agreed to issue the Consultant non-transferable share purchase warrants for the purchase of up to 300,000 shares of the Company at an exercise price of \$0.14 per warrant, exercisable for a period of 18 months from issuance.

About BioHarvest Sciences Inc.

Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent protected Biofarming technology. It is the first and only industrial large-scale plant cell growth technology capable of directly and constantly producing the active plant ingredients without the necessity to grow the plant itself. The technology has been already validated by Vinia, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest. By adapting this technology to the Cannabis plant, and building adequate cells production capacity, BioHarvest Sciences Inc.'s objective is to become the leading supplier of Cannabis for both the medicinal and recreational legal use. See the following hyperlink for a visual description of our Biofarming technology: BHSC's Biofarming Technology

BioHarvest Sciences Inc.

Dr. Zaki Rakib President and Chairman of the Board

For further information, please contact:

Dave Ryan, VP Investor Relations & Director

Phone: 1 (604) 622-1186 Email: dave@bioharvest.com







Forward-Looking Statements Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Neither Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release